Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MPP

Meet The Groups Leading Cannabis Legalization, Nominated For The Industry's Top Award

After a blowout event in Miami during the week of 4/20, the Benzinga Cannabis Capital Conference (CCC) is gearing up for a repeat performance in Chicago on Sept. 13-14.

Benzinga

YSRC wins crucial mandal parishad poll

AMARAVATI: Amidst high tension, YSRC candidate Danaboina Santosha Rupavani was elected as Duggirala mandal parishad president in Mangalagiri on Thursday.

The Times of India

Rupa Vani unanimously elected Duggirala MPP president

TDP MPTC member Zubeena elected vice-president

The Hindu

From analysis to the latest developments in health,
read the most diverse news in one place.

US Supreme Court considers ‘Remain in Mexico’ policy dispute

Under the policy, tens of thousands of asylum seekers were forced to wait in Mexico for their US court dates.

Al Jazeera

Biden asks Supreme Court for OK to scrap Trump’s Remain in Mexico policy on asylum-seeking migrants

WASHINGTON — Courts can’t force President Joe Biden to abide by former President Donald Trump’s “Remain in Mexico” policy indefinitely, especially since it puts vulnerable migrants in danger and hampers foreign relations.

Tribune News Service

Hyderabad cos get licence for Pfizer’s Covid pill

HYDERABAD: Apart from Hyderabad-based pharma major Aurobindo Pharma Limited, other city-based pharma players like Granules India Ltd, MSN Group and SMS Pharmaceuticals too have received licences from the UN-backed Medicines Patent Pool (MPP) to manufacture and supply a generic version of nirmatrelvir, a key component of Pfizer’s oral Covid-19 drug…

The Times of India

Aurobindo gets licence for supply of Pfizer’s Covid pill

HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.

The Times of India

Read news from The Economist, FT, and more,
with one subscription

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

The Hindu

Pfizer Commits 10M Courses Of COVID-19 Oral Antiviral To Developing Countries: Reuters

Pfizer Inc (NYSE:PFE) is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries in 2022, reports Reuters citing an official with the Global Fund. The Fund's head of strategy for policy, Harley Feldbaum, said Pfizer had committed at least that many…

Benzinga

Dad's death sent woman down dark path of drug and alcohol addiction

Kerry Wells said everything she had ever known 'became tipped on its head'

Liverpool Echo

Some asylum aspirants pin hopes on Trump-era policy

When the Biden administration extended a Trump-era policy to make asylum-seekers wait in Mexico for hearings in Brownsville, Texas, it was barely noticed _ the latest step in a slow-moving rollout to make asylum hearings available

The Independent UK

Dozens of firms to make cheap version of Merck COVID pill for poorer nations

Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck Co's COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.

Reuters

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Homeland Security

Medicines Patent Pool

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.